loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)-

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales Cabergoline

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Menu

    Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)-

    ACTIVE PHARMA INGREDIENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 261,124Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Skg Pharma's Generic Cabergoline Receives Approval in US
    Skg Pharma's Generic Cabergoline Receives Approval in US

    25 Jun 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218618

    FDA
    25 Jun 2024
    Share Share
    CF Pharma received HALAL certification
    CF Pharma received HALAL certification

    06 Jul 2019

    // PRESS RELEASE

    http://cfpharma.hu/archive/cf-pharma-received-halal-certification-copy-copy/

    PRESS RELEASE
    06 Jul 2019
    Share Share
    Ingenus Pharms' Generic Cabergoline Receives Approval in US
    Ingenus Pharms' Generic Cabergoline Receives Approval in US

    06 Aug 2018

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204735

    FDA
    06 Aug 2018
    Share Share
    Eisai Acquires All Global Development & Marketing Rights For Lorcaserin HCI
    Eisai Acquires All Global Development & Marketing Rights For Lorcaserin HCI

    05 Jan 2017

    // PR NEWSWIRE

    http://www.prnewswire.com/news-releases/eisai-acquires-all-global-development-and-marketing-rights-for-chronic-weight-management-treatment-lorcaserin-hci-300385785.html

    PR NEWSWIRE
    05 Jan 2017
    Share Share
    Drug Giant Pfizer Forced to Recall Medicines without Childproof Caps
    Drug Giant Pfizer Forced to Recall Medicines without Childproof Caps

    11 Mar 2015

    // Samantha Landy HERALD SUN

    http://www.heraldsun.com.au/news/victoria/drug-giant-pfizer-forced-to-recall-medicines-without-childproof-caps/story-fni0fit3-1227259055670

    Samantha Landy HERALD SUN
    11 Mar 2015
    Share Share